Use of Cryopreserved Hepatocytes as Part of an Integrated Strategy to Characterize In Vivo Clearance for Peptide-Antibody Conjugate Inhibitors of Nav1.7 in Preclinical Species

Engineering NaV1.7 Inhibitory JzTx-V Peptides with a Potency and Basicity Profile Suitable for Antibody Conjugation To Enhance Pharmacokinetics

(2019) Justin K. Murray et al.   ACS Chemical Biology

Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics

(2018) Lindsay B. Avery et al.   mAbs

Pharmacological characterization of potent and selective NaV1.7 inhibitors engineered from Chilobrachys jingzhao tarantula venom peptide JzTx-V

(2018) Bryan D. Moyer et al.   PLoS One

Discovery of Tarantula Venom-Derived NaV1.7-Inhibitory JzTx-V Peptide 5-Br-Trp24 Analogue AM-6120 with Systemic Block of Histamine-Induced Pruritis

(2018) Bin Wu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Avoiding globalisation of the prescription opioid epidemic

(2017) Keith Humphreys   LANCET

Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms

(2017) Claudia A. Castro Jaramillo et al.   mAbs

Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates

(2017) Miroslav Dostalek et al.   mAbs

Na V 1.7 as a pain target – From gene to pharmacology

(2017) Irina Vetter et al.   PHARMACOLOGY & THERAPEUTICS

Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury

(2017) Michal Pyzik et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins

(2017) Liming Liu   Protein & Cell

Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief

(2016) Edward C Emery et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys

(2016) Amita Datta-Mannan et al.   mAbs

Antibody Glycosylation and Its Impact on the Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies and Fc-Fusion Proteins

(2015) Liming Liu   JOURNAL OF PHARMACEUTICAL SCIENCES

The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies

(2015) Amita Datta-Mannan et al.   mAbs

Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics

(2015) Amita Datta-Mannan et al.   mAbs

Therapeutic antibodies: Discovery, design and deployment

(2015) Paul A. Ramsland et al.   MOLECULAR IMMUNOLOGY

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

(2015) Robert P Lyon et al.   NATURE BIOTECHNOLOGY

Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics

(2015) Angela Schoch et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pattern recognition receptors as potential therapeutic targets in inflammatory rheumatic disease

(2015) Lisa M Mullen et al.   ARTHRITIS RESEARCH & THERAPY

Impact of Glycation on Antibody Clearance

(2014) Jane Yang et al.   AAPS Journal

Strategic Approaches to Optimizing Peptide ADME Properties

(2014) Li Di   AAPS Journal

Next-generation optimized biotherapeutics — A review and preclinical study

(2014) Tadashi Ueda   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge

(2014) Bing Li et al.   mAbs

Differential Enzyme-Linked Immunosorbent Assay and Ligand-Binding Mass Spectrometry for Analysis of Biotransformation of Protein Therapeutics: Application to Various FGF21 Modalities

(2013) Todd Hager et al.   ANALYTICAL CHEMISTRY

Pharmacokinetics and Pharmacokinetic–Pharmacodynamic Correlations of Therapeutic Peptides

(2013) Lei Diao et al.   CLINICAL PHARMACOKINETICS

Neonatal Fc Receptor and its Role in the Absorption, Distribution, Metabolism and Excretion of Immunoglobulin G-Based Biotherapeutics

(2013) Craig Giragossian et al.   CURRENT DRUG METABOLISM

Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool

(2013) Y. Xu et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Physiochemical and Biochemical Factors Influencing the Pharmacokinetics of Antibody Therapeutics

(2012) Daniela Bumbaca et al.   AAPS Journal

Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?

(2012) Rong Deng et al.   Expert Opinion on Drug Metabolism & Toxicology

Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes

(2012) Randy Hecht et al.   PLoS One

Gain of function NaV1.7 mutations in idiopathic small fiber neuropathy

(2011) Catharina G. Faber et al.   ANNALS OF NEUROLOGY

Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences

(2011) W. Wang et al.   DRUG METABOLISM AND DISPOSITION

High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans

(2011) A. M. Goetze et al.   GLYCOBIOLOGY

Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics

(2010) C. Andrew Boswell et al.   BIOCONJUGATE CHEMISTRY

CNS Delivery Via Adsorptive Transcytosis

(2008) Françoise Hervé et al.   AAPS Journal